Business Context and Reporting Period
This Form 8-K Current Report was filed by OrthoPediatrics Corp. on October 15, 2024. The filing discloses the execution of new employment agreements with five Named Executive Officers, replacing prior agreements dated between 2014 and 2022. The Compensation Committee of the Board of Directors approved these arrangements.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation terms.
Executive Base Salaries (Annual)
- David R. Bailey (President and CEO): $550,000
- Fred L. Hite (CFO and COO): $501,000
- Joseph W. Hauser (President of Trauma and Deformity Correction): $400,000
- Gregory A. Odle (President of Scoliosis): $368,000
- Daniel J. Gerritzen (General Counsel, EVP of Legal, Secretary): $368,000
Material Changes
The primary material change is the replacement of existing employment contracts with new three-year agreements that automatically renew for successive one-year terms. The new agreements introduce specific severance structures and non-competition covenants not detailed in the summary of the prior contracts.
Guidance, Outlook, and Material Terms
Severance Provisions
Upon termination without "Cause" or for "Good Reason," or in the event of a "Change of Control" followed by termination or title change within 12 months, executives are entitled to:
- 30 months of annual base salary.
- 2.5 times the average bonus of the prior three fiscal years.
- Payments made in 30 substantially equal monthly installments.
- Lump-sum payments for unpaid earned bonuses and pro-rated performance bonuses.
- Up to 12 months of subsidized healthcare continuation.
Restrictive Covenants
Executives are subject to non-competition and non-solicitation restrictions for 30 months following termination, applicable in locations where the Company or the executive conducted business during the preceding 12 months.
Risks and Contingencies
Compensation is subject to clawbacks as required by law, regulation, or stock exchange listing requirements. Severance is contingent upon the execution of a general release of claims and compliance with restrictive covenants.
Investor Verification Checklist
- Review the full text of Exhibits 10.1 through 10.5 for specific definitions of "Cause," "Good Reason," and "Change of Control."
- Verify the total potential cash outflow for severance based on the 30-month salary and 2.5x bonus multiplier for each executive.
- Assess the impact of the 30-month non-compete period on executive mobility and potential litigation risks.
- Confirm the status of the annual bonus plan referenced in the agreements to understand variable compensation exposure.